含沃诺拉赞方案根除幽门螺杆菌研究进展  

Research progress in the eradication of Helicobacter pylori with Vanorazan regimen

作　　者：杜宏伟[1] 李挺 张爱萍[1] 林奕旻 金正旭 张德奎[2] DU Hongwei;LI Ting;ZHANG Aiping;LIN Yimin;JIN Zhengxu;ZHANG Dekui(Department of Gastroenterology,Lanzhou Second People’s Hospital,Gansu Province,Lanzhou730030,China;Department of Gastroenterology,the Second Hospital of Lanzhou University,Gansu Province,Lanzhou730030,China)

机构地区：[1]兰州市第二人民医院消化科,甘肃兰州730030 [2]兰州大学第二医院消化科,甘肃兰州730030

出　　处：《中国医药导报》2022年第24期44-47,76,共5页China Medical Herald

基　　金：甘肃省重点研发计划-社会发展类项目(20YF8FA078);甘肃省兰州市城关区科技计划项目(2018SHFZ0037)。

摘　　要：幽门螺杆菌(Hp)与慢性胃炎、消化性溃疡及胃癌的发病密切相关。含质子泵抑制剂方案治疗Hp的根除率逐渐下降。沃诺拉赞(VPZ)是一种新型钾离子竞争性酸阻滞剂,可以竞争性地抑制K~+与H~+-K~+-ATPase的结合来抑制胃壁细胞的酸分泌,国际上已有多项含VPZ方案用于根除Hp的一线、二线治疗方案的报道,本文就此作一综述。Helicobacter pylori(Hp)is closely related to chronic gastritis,peptic ulcer,and gastric cancer.The eradication rate of Hp with proton pump inhibitor decreased gradually.Vonoprazan(VPZ)is a new potassium ion competitive acid blocker,which can competitively inhibit the combination of Kand H-K-ATPase to inhibit the acid secretion of gastric parietal cells.There have been a number of international reports on the first-line and second-line treatment regimen containing VPZ for eradicating Hp,which are reviewed in this paper.

关 键 词：幽门螺杆菌 质子泵抑制剂 沃诺拉赞 根除率 

分 类 号：R573[医药卫生—消化系统]